Capital World Investors Cuts Position in Krystal Biotech, Inc. $KRYS

Capital World Investors decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 809,240 shares of the company’s stock after selling 133,009 shares during the quarter. Capital World Investors owned 2.79% of Krystal Biotech worth $142,855,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Sound View Wealth Advisors Group LLC grew its holdings in Krystal Biotech by 2.9% in the third quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after purchasing an additional 56 shares during the period. Bessemer Group Inc. increased its position in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Krystal Biotech by 1.3% during the 3rd quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock worth $1,129,000 after buying an additional 81 shares during the period. Main Management ETF Advisors LLC raised its stake in shares of Krystal Biotech by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after buying an additional 84 shares during the period. Finally, M&T Bank Corp lifted its position in shares of Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock valued at $520,000 after buying an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 2.3%

Shares of NASDAQ KRYS opened at $255.00 on Thursday. The stock has a market cap of $7.45 billion, a PE ratio of 37.23 and a beta of 0.49. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $298.30. The company has a 50-day moving average of $270.39 and a 200 day moving average of $221.13.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $107.11 million for the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This represents a 39.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Janney sold 37,895 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $266.88, for a total value of $10,113,417.60. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 129,164 shares of company stock worth $34,538,578. 13.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 18th. The Goldman Sachs Group increased their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a report on Friday, January 30th. Citigroup lifted their target price on shares of Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Chardan Capital lifted their price objective on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $326.25.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.